Management of pregnant women infected with COVID-19
Authors: Yongwen Luo, Kai Yin
Journal: The Lancet Infectious Diseases (2020)

Since December, 2019, the outbreak of coronavirus disease 2019 (COVID-19), which originated in Wuhan, China, has become a global public health threat.1Li Q Guan X Wu P et al.Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.N Engl J Med. 2020; (published online Jan 29.)DOI:10.1056/NEJMoa2001316Crossref Scopus (10671) Google Scholar On Feb 28, 2020, WHO upgraded their assessment of the risk of spread and the risk of impact of COVID-19 to very high at global level. By March 10, 2020, 116 166 cases have been reported globally, causing 4088 deaths. The epidemic has spread to 118 countries around the world.2WHOCoronavirus disease 2019 (COVID-2019) situation report 46.https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_2Date: March 6, 2020Date accessed: March 6, 2020Google Scholar With immunocompromised status and physiological adaptive changes during pregnancy, pregnant women could be more susceptible to COVID-19 infection than the general population. As COVID-19 is rapidly spreading, maternal management and fetal safety become a major concern, but there is scarce information of assessment and management of pregnant women infected with COVID-19, and the potential risk of vertical transmission is unclear. In The Lancet Infectious Diseases, Nan Yu and colleagues3Yu N Wei L Kang Q et al.Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.Lancet. 2020; (published online Mar 24.)https://doi.org/10.1016/S1473-3099(20)30176-6Summary Full Text Full Text PDF Scopus (570) Google Scholar report the clinical features and obstetric and neonatal outcomes of pregnancy with COVID-19 pneumonia in Wuhan, China. Seven pregnant women with COVID-19 pneumonia were assessed and the onset symptoms were similar to those reported in non-pregnant adults with COVID-19. All patients received oxygen therapy and antiviral treatment in isolation. All patients had caesarean section after consultation with a multidisciplinary team and the outcomes of the pregnant women and neonates were good. Three neonates were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and one was found to be infected with COVID-19 36 h after birth. The findings of the study provide some indications for clinical assessment and management of pregnant women with COVID-19, but questions remain on how to manage pregnant women infected with COVID-19. As Yu and colleagues3Yu N Wei L Kang Q et al.Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.Lancet. 2020; (published online Mar 24.)https://doi.org/10.1016/S1473-3099(20)30176-6Summary Full Text Full Text PDF Scopus (570) Google Scholar reported, five pregnant women were treated with steroids after caesarean section. Two were also treated with traditional Chinese medicine. However, no reliable evidence recommends any specific COVID-19 treatment for pregnant women. WHO guidance and some clinical evidence does not recommend the use of corticosteroids for COVID-19.4WHOClinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected.https://www.who.int/publications-detail/clinical-management-of-severeacute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-issuspectedDate: Jan 28, 2020Date accessed: March 6, 2020Google Scholar, 5Russell CD Millar JE Baillie JK Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.Lancet. 2020; 395: 473-475Summary Full Text Full Text PDF PubMed Scopus (1531) Google Scholar Use of drugs in pregnant women needs to be on the basis of solid evidence. Clinical trials are needed to prove the effectiveness of drugs and the effects on the fetus to establish a standardised treatment for pregnant women with COVID-19. More evidence of the safety of traditional Chinese medicine is also warranted. The time of delivery in the study was 37 weeks to 41 weeks plus 5 days, all by caesarean section. In cases of pregnant women with COVID-19, more evidence is needed to establish when to deliver and when caesarean sections should be recommended. Previous treatment experience has been inconclusive about which delivery method is safer in this patient population. Zhu and colleagues6Zhu H P L W Cheng Z F et al.Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia.Transl Pediatr. 2020; (published online Feb 10.)DOI:10.21037/tp.2020.02.06Crossref Scopus (934) Google Scholar reported nine pregnant women with COVID-19. Seven of the women delivered their babies by cesarean section and two by vaginal delivery. All three neonates delivered vaginally (including two who were twins) had an Apgar score of at least 9 and negative nucleic acid test. Yudin and colleagues7Yudin MH Steele DM Sgro MD Read SE Kopplin P Gough KA Severe acute respiratory syndrome in pregnancy.Obstet Gynecol. 2005; 105: 124-127Crossref PubMed Scopus (60) Google Scholar reported a pregnant woman with SARS at 31 weeks of gestation; the patient stayed for 21 days in the hospital and did not require intensive care admission or ventilatory support, and a healthy baby girl was delivered by vaginal birth. It is unknown whether vaginal delivery increases the infection risk. Further research is needed to assess the risk and to produce guidelines for delivery times and methods in patients with COVID-19. As discussed in the study, although all mothers and infants showed good outcomes, all enrolled pregnant women were in the third trimester, and all had only mild symptoms. Hence, the effect of SARS-CoV-2 infection on the fetus in the first or second trimester or in patients with moderate to severe infection is unknown. As a previous study reported, SARS coronavirus infection during pregnancy might cause preterm birth, intrauterine growth restriction, intrauterine death, and neonatal death.8Lam CM Wong SF Leung TN et al.A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome.BJOG. 2004; 111: 771-774Crossref PubMed Scopus (196) Google Scholar Considering that the potential of SARS-CoV-2 to cause severe obstetric and neonatal adverse outcomes is unknown, rigorous screening of suspected cases during pregnancy and long-term follow-up of confirmed mothers and their neonates are needed. In the study by Yu and colleagues,3Yu N Wei L Kang Q et al.Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.Lancet. 2020; (published online Mar 24.)https://doi.org/10.1016/S1473-3099(20)30176-6Summary Full Text Full Text PDF Scopus (570) Google Scholar three neonates were tested for SARS-CoV-2, of whom two were negative. One neonate was positive, but the viral nucleic acid tests of the placenta and cord blood in this case were negative. At the end of follow-up, no pneumonia and other clinical symptoms and signs were reported in any of the seven neonates. No reliable evidence has been provided in support of the possibility of vertical transmission of COVID-19 infection from mother to baby. The outcomes are consistent with previous reports.9Chen S Huang B Luo DJ et al.Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases.Zhonghua Bing Li Xue Za Zhi. 2020; 49 (in Chinese).: E005PubMed Google Scholar, 10Chen H Guo J Wang C et al.Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.Lancet. 2020; 395: 809-815Summary Full Text Full Text PDF PubMed Scopus (2639) Google Scholar But all these studies only assessed a small number of cases. Future studies should include a larger number of samples across multiple centres to establish whether vertical transmission can occur between mother and child. Yu and colleagues'3Yu N Wei L Kang Q et al.Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.Lancet. 2020; (published online Mar 24.)https://doi.org/10.1016/S1473-3099(20)30176-6Summary Full Text Full Text PDF Scopus (570) Google Scholar report of the clinical features and obstetric and neonatal outcomes of pregnant women with COVID-19 provides a reference for clinical assessment and management of this patient population. However, understanding of SARS-CoV-2, especially the effect on pregnant women and neonates, is still insufficient. We need to further strengthen research to provide an evidence-based foundation for the medical management of pregnant patients with COVID-19. We declare no competing interests. We provided the management and follow-up information for the neonate positive for SARS-CoV-2 described in the paper by Yu and colleagues; we were not involved in the management of the pregnant women described in the paper. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive studyThe maternal, fetal, and neonatal outcomes of patients who were infected in late pregnancy appeared very good, and these outcomes were achieved with intensive, active management that might be the best practice in the absence of more robust data. The clinical characteristics of these patients with COVID-19 during pregnancy were similar to those of non-pregnant adults with COVID-19 that have been reported in the literature. Full-Text PDF